朝闻国盛：七月配置建议：不轻易低配A股

Group 1: Market Overview and Strategy - The report emphasizes the importance of actively participating in market breakthroughs and focusing on performance pricing cues, particularly in sectors like consumer goods, precious metals, and engineering machinery [2] - In June, despite increased geopolitical tensions, risk appetite improved overall, leading to a recovery in equity assets, with major indices in A-shares experiencing upward breakthroughs [2] - The report suggests increasing trading positions to capitalize on strong breakout directions while prioritizing performance certainty in investment allocations [2] Group 2: Financial Engineering and Investment Value - The report discusses the use of DeepSeek to assist fund managers in reducing tracking errors relative to benchmarks, highlighting its capabilities in strategy implementation and code generation [3][4] - The analysis of the 华夏中证生物科技主题 ETF indicates that the demand for innovative drugs is driven by structural upgrades and policy support, with a significant increase in the number of innovative drugs included in the national medical insurance directory [6][7] - The 中证生物科技主题指数 reflects the overall performance of biotechnology stocks, with a focus on sectors like biopharmaceuticals and medical devices, indicating a high concentration of leading companies [8] Group 3: Company-Specific Insights - The report on 容知日新 (688768.SH) highlights its strong gross margin above 60% and net margin near 20%, driven by predictive maintenance solutions that align with industry trends [12] - Revenue projections for 容知日新 are set at 7.91 billion, 10.23 billion, and 12.88 billion CNY for 2025-2027, with corresponding net profits of 1.44 billion, 1.94 billion, and 2.56 billion CNY, indicating robust growth potential [12] - The report on the domestic optical module market suggests that companies like 华工科技 and 中际旭创 are well-positioned to benefit from high demand and supply shortages in the optical communication sector [16] Group 4: Emerging Trends and Innovations - The report notes that the pain relief market is evolving with a shift towards non-opioid medications, driven by innovations in pain management mechanisms [16] - The entry of Robinhood into the tokenized U.S. stock market is expected to accelerate the development of this sector, potentially leading to significant regulatory advancements [14][15] - The analysis of the biotechnology sector indicates a strong long-term growth outlook due to aging demographics and increasing healthcare spending, with innovative drugs gaining traction in the market [7][8]